Purpose: To investigate the diagnostic value of F-fluoroethyl-L-tyrosine (FET) positron emission tomography (PET) in patients with suspected tumefactive demyelinating disease.
Methods: We retrospectively examined FET-PET and MR imaging of 21 patients (12 female, 9 male) with known demyelinating disease and newly diagnosed tumefactive lesions. The maximum standardized uptake value (SUVmax), time activity curves (TAC) and lesion-to-background ratio (TBR) of these lesions were calculated. The standard of reference consisted of biopsy and/or follow-up imaging. FET parameters of true neoplastic lesions and tumefactive demyelinating lesions were compared using Mann-Whitney U-test and receiver operating characteristic (ROC) analysis.
Results: Nine patients (42.9%) had neoplastic lesions, 12 patients (57.1%) had tumefactive demyelinating lesions. TBRmax, SUVmax and TAC were significantly different between demyelinating lesions and neoplastic lesions: Tumors had a higher TBRmax (3.53 ± 1.09 vs. 1.48 ± 0.31, respectively; P < 0.001) and SUVmax (3.95 ± 1.59 vs. 1.86 ± 0.50, respectively; P < 0.001) than tumefactive demyelinating lesions. The TAC of tumors was significantly higher compared to tumefactive demyelinating lesions at all time points (P < 0.05). ROC analysis revealed that a TBRmax threshold of 2.2 and a SUVmax threshold of 2.5 could reliably differentiate tumor and tumefactive demyelination (area under the curve, 1.000 and 0.958, respectively).
Conclusion: In patients with demyelinating disease, FET-PET parameters TBRmax (cut-off 2.2) and SUVmax (cut-off 2.5) are able to distinguish tumefactive demyelinations from true neoplastic lesions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000002244 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tissue Is the Issue: The Diagnosis of Butterfly Brain Lesions.
Cureus
December 2024
Neurology, Palmetto General Hospital, Hialeah, USA.
The corpus callosum can reveal a "butterfly" pattern on imaging in various conditions, including glioblastoma, primary central nervous system lymphoma, tumefactive multiple sclerosis, and toxoplasmosis. Early differentiation among these conditions is crucial to avoid aggressive treatments. In one case, a 70-year-old woman with a history of multiple sclerosis experienced a neurological decline.
View Article and Find Full Text PDFDeep learning MRI models for the differential diagnosis of tumefactive demyelination versus -wildtype glioblastoma.
AJNR Am J Neuroradiol
January 2025
From the Department of Radiology (GMC, MM, YN, BJE), Department of Quantitative Health Sciences (PAD, MLK, JEEP), Department of Neurology (CBM, JAS, MWR, FSG, HKP, DHL, WOT), Department of Neurosurgery (TCB), Department of Laboratory Medicine and Pathology (RBJ), and Center for Multiple Sclerosis and Autoimmune Neurology (WOT), Mayo Clinic, Rochester, MN, USA; Dell Medical School (MFE), University of Texas, Austin, TX, USA.
Background And Purpose: Diagnosis of tumefactive demyelination can be challenging. The diagnosis of indeterminate brain lesions on MRI often requires tissue confirmation via brain biopsy. Noninvasive methods for accurate diagnosis of tumor and non-tumor etiologies allows for tailored therapy, optimal tumor control, and a reduced risk of iatrogenic morbidity and mortality.
View Article and Find Full Text PDFCNS B cell infiltration in tumefactive anti-myelin oligodendrocyte glycoprotein antibody-associated disease.
Mult Scler J Exp Transl Clin
December 2024
Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan.
Background: Few studies have examined B cells among patients with anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), including brain pathology.
Objective: To describe cases of tumefactive MOGAD with B-cell dominant central nervous system (CNS) infiltration.
Methods: In this study, we reviewed three cases with clinical and brain histopathological features with tumefactive MOGAD.
Establishment of an MRI-based radiomics model for distinguishing between intramedullary spinal cord tumor and tumefactive demyelinating lesion.
BMC Med Imaging
November 2024
School of Medicine, Southeast University, Nanjing, China.
Objective: Differentiating intramedullary spinal cord tumor (IMSCT) from spinal cord tumefactive demyelinating lesion (scTDL) remains challenging with standard diagnostic approaches. This study aims to develop and evaluate the effectiveness of a magnetic resonance imaging (MRI)-based radiomics model for distinguishing scTDL from IMSCT before treatment initiation.
Methods: A total of 75 patients were analyzed in this retrospective study, comprising 55 with IMSCT and 20 with scTDL.
Etiology and characteristics of pseudotumoral lesions and tumefactive demyelination in multiple sclerosis.
Mult Scler Relat Disord
December 2024
Faculty of Medicine, University of Belgrade, Serbia; Neurology Clinic, University Clinical Center of Serbia, Serbia. Electronic address:
Article Synopsis
- The study focused on cerebral pseudotumoral lesions (CPTL) greater than 2 cm, primarily in patients referred for evaluation of multiple sclerosis (MS).
- Most of the 75 patients studied had MS (58.7%), with relapsing disease and specific lesion characteristics being significantly more common in this group compared to non-MS patients.
- Key indicators such as headache, the nature of disease progression, and certain MRI traits could help differentiate between MS and non-MS conditions, suggesting a need for further research with larger sample sizes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!